Veran Medical Technologies (St. Louis, MO, USA) has recently received two clearances (K093146 & K093995) from the U.S. Food and Drug Administration (FDA) to expand its indications for use of the ig4 Navigation platform.

“History has shown that the delivery of therapies in a cost-effective, reliable, and efficient manner is as important as the therapy itself. We are excited about the near future when we will have tightly integrated therapy and delivery as well. These clearances allow Veran to be a market-unlocking key in driving the growth of minimally invasive interventional oncology procedures,” said Les Carlson, Veran director of percutaneous products.

Veran Medical Technologies is a medical device company focused on developing the next standard of care for minimally invasive delivery of interventional oncology therapies. Veran provides proprietary 4D registration capability for precise targeting of lesions via its electromagnetic navigation platform. The Veran platform aims to reduce procedure times, reduce radiation exposure for the clinical staff, and increase targeting accuracy enabling physicians to cost effectively treat patients with reduced comorbidity risk. The company believes that by enabling minimally invasive, early stage treatments, it can increase patient survival and lower healthcare costs significantly.

Related Links:
Veran Medical Technologies